Emerald Mutual Fund Advisers Trust Has $13.65 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Mutual Fund Advisers Trust lowered its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 324,437 shares of the biopharmaceutical company’s stock after selling 104,865 shares during the quarter. Emerald Mutual Fund Advisers Trust owned 0.35% of Ultragenyx Pharmaceutical worth $13,649,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of RARE. First Light Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 1.1% in the fourth quarter. First Light Asset Management LLC now owns 763,607 shares of the biopharmaceutical company’s stock valued at $32,125,000 after buying an additional 8,505 shares in the last quarter. Northern Trust Corp boosted its stake in Ultragenyx Pharmaceutical by 11.8% in the 4th quarter. Northern Trust Corp now owns 528,965 shares of the biopharmaceutical company’s stock worth $22,254,000 after purchasing an additional 55,641 shares during the period. Quarry LP bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth about $84,000. Aquatic Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 327.4% in the 4th quarter. Aquatic Capital Management LLC now owns 102,571 shares of the biopharmaceutical company’s stock valued at $4,315,000 after purchasing an additional 78,571 shares during the period. Finally, Birchview Capital LP bought a new stake in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $673,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Trading Down 0.3 %

RARE stock opened at $37.98 on Tuesday. The business’s 50 day simple moving average is $37.79 and its 200 day simple moving average is $43.54. Ultragenyx Pharmaceutical Inc. has a 1-year low of $29.59 and a 1-year high of $60.37. The firm has a market capitalization of $3.57 billion, a PE ratio of -5.99 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. As a group, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 73,434 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the completion of the sale, the chief executive officer now directly owns 641,731 shares in the company, valued at approximately $27,016,875.10. The trade was a 10.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Howard Horn sold 1,785 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the sale, the chief financial officer now owns 106,169 shares of the company’s stock, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,643 shares of company stock worth $5,256,268. Company insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. increased their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Wedbush reiterated a “neutral” rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Finally, Piper Sandler decreased their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.